Rodrigo Martín

Rodrigo Martín

Auto-generated profile, based on publicly available information

Rodrigo Martín

Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NGNicolás Gaitán
Nicolás Gaitán
RMRodrigo Martín
Rodrigo Martín
DTDaniel Tello
Daniel Tello
EBElisa Benetti
Elisa Benetti
MRMichela Riba
Michela Riba
DTDavid Torrents
David Torrents
The study of somatic variants from tumor genomes is fundamental to cancer research and clinical decision-making. However, existing data protection frameworks impose restrictions on the use and sharing of these variants in conjunction with sensitive germline information. To overcome these challenges, we developed GenomeAnonymizer, the first method to anonymize short-read DNA sequences from tumor-normal pairs. This generates Somatic Tumor Twins (STTs), an anonymized version of the original data that preserves the donor’s privacy while retaining somatic tumor information and sequencing noise. This method successfully removed all detectable germline variants from the 47 PCAWG-Pilot samples. We further demonstrate that Whole-Genome Sequencing (WGS) STTs preserve more than 98% of the original somatic variants, enabling reliable downstream analysis that replicates somatic-related findings from the original samples, including cancer driver genes, mutational signatures, and intratumor heterogeneity. Importantly, we also show that STTs can reproduce the identification of actionable genes and downstream clinical interpretations and decision-making. We generated a cancer cohort of STTs matched with synthetic clinical data that could be openly shared and used across projects and centers worldwide. This paradigm-shifting approach will accelerate discovery and clinical translation in oncology and enable the robust benchmarking of genome analysis and large-scale data infrastructures.

24 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LALorena Alonso
Lorena Alonso
MPMiguel Ángel Pérez-Elena
Miguel Ángel Pérez-Elena
Mohammed Yousef Salem AliMohammed Yousef Salem Ali
Mohammed Yousef Salem Ali
MMMaedeh Mashhadikhan
Maedeh Mashhadikhan
NGNicolás Gaitán
Nicolás Gaitán
DTDavid Torrents
David Torrents
Type 2 diabetes (T2D) is a complex and clinically heterogeneous disease. Although clustering approaches have defined clinical subtypes, their genetic and molecular architectures remain poorly understood. Efforts using genome-wide association studies (GWAS) have been constrained by modest sample sizes and conservative significance thresholds, limiting subgroup resolution. Leveraging recent expansions in cohort scale and diversity, we developed a new analytical framework that integrates GWAS with Machine Learning and eXplainable Artificial Intelligence. Applied to the UK Biobank, this strategy enabled the first comprehensive genetic and molecular characterization of T2D subtypes, identifying 184 genes that define each subgroup’s molecular landscape and associated tissue profiles. In addition, the framework improved detection of T2D risk compared to current Polygenic Risk Scores. The findings underscore the importance of clinical stratification to uncover the complex pathophysiology of T2D and to pave the way for more precise prevention and treatment strategies.